Pharming Group N.V.
LEI 724500DCJ9MPG74JEH91Netherlandsfmd_14ZY0ZRCC1HSNJ6RQ1TTYGN3RATemplate: Standard
This company files annual reports on an EU or UK regulated market, not with the SEC. Statements come from its ESEF annual report in USD and are not converted. Ownership, prices, dividends and events are built from SEC and US market data and are not available for it.
Coverage: Jan 01, 2020 to Dec 31, 2025, 6 periods
Latest annual · FY2025
Millions- Total revenues
- 376
- Gross profit
- 331
- Operating income
- 26
- Net income
- 3
- Free cash flow
- 54
Bulls and bears
News summary
An AI model writes the summary on request, from this company's recent filings only, and cites each filing it uses.
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- +22.3%
- Revenue, 5 yearsFY2020 to FY2025
- +12.1%
- Net income, 5 yearsFY2020 to FY2025
- -40.3%
Pharming Group N.V. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $376.1 million | $297.2 million | +26.6% | AFR 2026-04-02 · proof |
| Gross profit | $330.6 million | $261.8 million | +26.3% | AFR 2026-04-02 · proof |
| Operating income | $25.8 million | -$8.6 million | AFR 2026-04-02 · proof | |
| Net income | $2.9 million | -$11.8 million | AFR 2026-04-02 · proof | |
| Cash from operating activities | $54.7 million | -$1.8 million | AFR 2026-04-02 · proof | |
| Free cash flow | $54 million | -$2.6 million | AFR 2026-04-02 · proof | |
| Total assets | $500 million | $400 million | +25% | AFR 2026-04-02 · proof |
| Total liabilities | $222.9 million | $178.9 million | +24.6% | AFR 2026-04-02 · proof |
| Cash and cash equivalents | $145.3 million | $54.9 million | +164.5% | AFR 2026-04-02 · proof |
- What was Pharming Group N.V.'s revenue in fiscal 2025?
- Pharming Group N.V. reported revenue of $376.1 million for fiscal 2025 (the year ended Dec 31, 2025), against $297.2 million the year before (+26.6%). Source: the AFR filed with the SEC on Apr 2, 2026. SEC
- What was Pharming Group N.V.'s gross profit in fiscal 2025?
- Pharming Group N.V. reported gross profit of $330.6 million for fiscal 2025 (the year ended Dec 31, 2025), against $261.8 million the year before (+26.3%). Source: the AFR filed with the SEC on Apr 2, 2026. SEC
- What was Pharming Group N.V.'s operating income in fiscal 2025?
- Pharming Group N.V. reported operating income of $25.8 million for fiscal 2025 (the year ended Dec 31, 2025), against -$8.6 million the year before. Source: the AFR filed with the SEC on Apr 2, 2026. SEC
- What was Pharming Group N.V.'s net income in fiscal 2025?
- Pharming Group N.V. reported net income of $2.9 million for fiscal 2025 (the year ended Dec 31, 2025), against -$11.8 million the year before. Source: the AFR filed with the SEC on Apr 2, 2026. SEC
- What was Pharming Group N.V.'s cash from operating activities in fiscal 2025?
- Pharming Group N.V. reported cash from operating activities of $54.7 million for fiscal 2025 (the year ended Dec 31, 2025), against -$1.8 million the year before. Source: the AFR filed with the SEC on Apr 2, 2026. SEC
- What was Pharming Group N.V.'s free cash flow in fiscal 2025?
- Pharming Group N.V. reported free cash flow of $54 million for fiscal 2025 (the year ended Dec 31, 2025), against -$2.6 million the year before. Source: the AFR filed with the SEC on Apr 2, 2026. SEC
- What are Pharming Group N.V.'s total assets?
- As of Dec 31, 2025, Pharming Group N.V. reported total assets of $500 million, against $400 million a year earlier (+25%). Source: the AFR filed with the SEC on Apr 2, 2026. SEC
- What are Pharming Group N.V.'s total liabilities?
- As of Dec 31, 2025, Pharming Group N.V. reported total liabilities of $222.9 million, against $178.9 million a year earlier (+24.6%). Source: the AFR filed with the SEC on Apr 2, 2026. SEC
- What are Pharming Group N.V.'s cash and cash equivalents?
- As of Dec 31, 2025, Pharming Group N.V. reported cash and cash equivalents of $145.3 million, against $54.9 million a year earlier (+164.5%). Source: the AFR filed with the SEC on Apr 2, 2026. SEC
Read from the FinancialMD API on Nov 19, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=fmd_14ZY0ZRCC1HSNJ6RQ1TTYGN3RA&period_type=annual&limit=5"Information only, not investment advice.